At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed May 13, 2026 at 08:00 ET
Protara Therapeutics reported Q1 2026 net loss of $0.31 per share, beating consensus estimates of $0.37 loss, with cash of $177.4M to fund operations into 2028. Pipeline progress includes planned BLA submission for TARA-002 in lymphatic malformations in 2H 2027 and multiple data presentations in May 2026.
- Q1 2026 net loss $17.8M ($0.31/share) vs consensus $0.37 loss per share
- Cash, equivalents and marketable securities $177.4M as of March 31, 2026
- Plan to submit BLA for TARA-002 in LMs in 2H 2027
- Enrollment completion for BCG-Unresponsive cohort in ADVANCED-2 trial expected 2H 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access